Study summary · research use only
Synergistic Effects of Injectable Platelet-Rich Fibrin and Bioactive Peptides on Dermal Fibroblast Viability and Extracellular Matrix Gene Expression: An In Vitro Study
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This in vitro study using human dermal fibroblasts examined injectable platelet-rich fibrin (i-PRF) combined with the cosmetic peptides palmitoyl pentapeptide-4 (Matrixyl) or Tetrapeptide-21 (GEKG), testing six conditions: control, i-PRF alone, Matrixyl alone, GEKG alone, i-PRF plus Matrixyl, and i-PRF plus GEKG. Viability and proliferation were measured by MTT, crystal violet, and RealTime-Glo assays, and expression of COL1A1, FN1, and HAS1 was measured by RT-qPCR. The combinations, especially i-PRF plus GEKG, were associated with increased cell viability and upregulated extracellular-matrix-related gene expression at 72 h, with stronger effects than the individual treatments, particularly with GEKG. The authors state further preclinical and clinical studies are needed.
Abstract
Facial aging is a multifactorial process involving changes in bone, fat compartments, ligaments, muscles, and skin. Collagen biostimulators, including synthetic agents and autologous platelet concentrates, have gained attention for facial rejuvenation. Injectable platelet-rich fibrin (i-PRF), a second-generation autologous concentrate, has shown promising regenerative properties due to its natural composition and growth factors. Cosmetic peptides, such as palmitoyl pentapeptide-4 (Matrixyl) and Tetrapeptide-21 (GEKG), are also studied for their ability to stimulate collagen synthesis and remodel the extracellular matrix. This in vitro study examined the potential synergistic effects of i-PRF combined with Matrixyl or GEKG on human dermal fibroblast viability, proliferation, and ECM-related gene expression. Fibroblasts were cultured under six conditions: control, i-PRF alone, Matrixyl alone, GEKG alone, i-PRF + Matrixyl, and i-PRF + GEKG. Viability and proliferation were assessed via MTT, crystal violet, and RealTime-Glo™ assays. Gene expression of COL1A1, FN1, and HAS1 was measured using RT-qPCR. The combinations, especially i-PRF + GEKG, led to increased cell viability and upregulated ECM-related genes at 72 h. These effects were stronger than the individual treatments, suggesting synergistic effects, especially with GEKG. These findings highlight the clinical potential of combining autologous platelet concentrates with bioactive peptides for dermal regeneration. Further preclinical and clinical studies are warranted.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.